MorphoSys AG (MOR) Given a €85.00 Price Target at Berenberg Bank

Berenberg Bank set a €85.00 ($100.00) target price on MorphoSys AG (ETR:MOR) in a research report sent to investors on Wednesday morning. The firm currently has a buy rating on the stock.

MOR has been the topic of a number of other research reports. J P Morgan Chase & Co set a €62.00 ($72.94) target price on MorphoSys AG and gave the company a neutral rating in a research note on Friday, August 4th. Goldman Sachs Group, Inc. (The) set a €55.00 ($64.71) target price on MorphoSys AG and gave the company a neutral rating in a research note on Monday, July 17th. Commerzbank Ag set a €76.00 ($89.41) target price on MorphoSys AG and gave the company a buy rating in a research note on Wednesday, September 6th. Deutsche Bank AG set a €90.00 ($105.88) target price on MorphoSys AG and gave the company a buy rating in a research note on Tuesday, August 1st. Finally, Independent Research GmbH set a €84.00 ($98.82) target price on MorphoSys AG and gave the company a buy rating in a research note on Wednesday, October 4th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has an average rating of Buy and a consensus target price of €79.00 ($92.94).

MorphoSys AG (ETR MOR) opened at €80.02 ($94.14) on Wednesday. MorphoSys AG has a 52 week low of €38.14 ($44.87) and a 52 week high of €80.67 ($94.91).

COPYRIGHT VIOLATION NOTICE: This report was originally published by BBNS and is the sole property of of BBNS. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://baseballnewssource.com/markets/morphosys-ag-mor-given-a-85-00-price-target-at-berenberg-bank/1747326.html.

MorphoSys AG Company Profile

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for MorphoSys AG (ETR:MOR)

Receive News & Ratings for MorphoSys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys AG and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.